Lineage Cell Therapeutics Q1 net loss widens as expenses rise

Lineage Cell Therapeutics

12/05/2026 21:09

Overview

US cell therapy developer's Q1 revenue rose slightly, driven by collaboration agreement

Q1 net loss widened year-over-year as operating expenses increased

Company advanced OpRegen clinical program and launched new corneal cell therapy initiative

Outlook

Company expects cash and marketable securities to support operations into Q2 2028

Company will continue to advance its cell therapy pipeline through internal spending and external partnerships

Result Drivers

COLLABORATION REVENUE - Revenue increase was primarily driven by collaboration revenue recognized under new research collaboration agreement with WDI

R&D SPENDING - Higher R&D expenses were mainly due to increased spending on OPC1, ReSonance, and preclinical programs

PERSONNEL COSTS - G&A expenses rose slightly, primarily due to personnel costs

Company press release: ID:nBw5f6C1Za

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.03
Q1 Net Income
-$4.79 mln
Q1 Income from Operations
-$7.59 mln
Q1 Operating Expenses
$9.32 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lineage Cell Therapeutics Inc is $4.50, about 243.5% above its May 11 closing price of $1.31

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)